Últimas noticias sobre CK Hutchison Holdings (OTC:CKHUF) Bolsa

CK Hutchison Holdings, or CKH, is a Hong Kong headquartered conglomerate with key businesses in ports, retail, infrastructure, and telecommunications. The company was created in 2015 to house the merged assets of Cheung Kong Holdings and Hutchison Whampoa as the group sought to flatten out and simplify its original holding structure. CKH contains most of the businesses previously housed in Hutchison Whampoa, minus the property assets, which were spun off into their own listing, CK Asset Holdings. Telecommunications and infrastructure activities now make up the largest share of EBITDA, at around 53%. The planned sale of most of the ports business is currently being scrutinized by the government.

Quantum computing firm&nbsp;IonQ Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) saw a price target hike from Benchmark after the company successfully raised $1 billion through an equity offering at $55.49 per share, a notable 25% premium to the closing price last Thursday.
What Happened: The equity offering is likely to bring IonQ&#8217;s pro-forma cash to an estimated $1.68 billion, accelerating the company&#8217;s commercialization efforts. Benchmark analyst David Williams has reiterated a Buy rating on IonQ shares and increased his price target from $50 to $55, expressing confidence in IonQ&#8217;s potential in the quantum computing market, <a href="https://www.barrons.com/articles/ionq-stock-offering-buy-rating-be632dc5?">reported </a>Barrons.
The price target was raised following a fireside chat between Benchmark analysts and IonQ CEO Niccolo de Masi and CFO Thomas Kramer, which strengthened the firm's optimistic view of the company.
Williams highlighted IonQ&#8217;s unique approach, which includes &#8220;positioning itself as a leader in both quantum computing and the increasingly critical field of quantum networking.&#8221; He also noted the company&#8217;s plans to gradually scale up its quantum machines, expressing confidence in its technical roadmap.
The company&#8217;s CEO, Niccolo de Masi, has underscored IonQ&#8217;s focus on quantum networking as a more feasible approach to constructing larger quantum computers. 
IonQ is widely seen as having the most commercially focused and differentiated business model and market strategy in the quantum computing space. The company has set bold targets, aiming to expand from 256 physical qubits in 2026 to 2 million physical qubits and 80,000 logical qubits by 2030. Williams says its highly commercial and differentiated strategy positions the company well as the industry evolves.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/tech/25/07/46272105/jack-dorsey-unveils-bitchat-a-decentralized-bluetooth-powered-server-free-messaging-service" target="_blank" rel="noreferrer noopener">Jack Dorsey Unveils &#8216;Bitchat,&#8217; A Decentralized, Bluetooth-Powered, Server-Free Messaging Service</a>
Why It Matters: The quantum computing industry is gaining significant investor attention due to its long-term economic potential, with IonQ being a standout frontrunner, <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46229237/cash-rich-ionq-to-capture-20-of-quantum-market-by-2035-analyst">according to</a> Cantor Fitzgerald analyst Troy Jensen. Despite its nascent stage, the industry is seeing substantial stock valuations, with IonQ expected to capture 20% of the quantum market by 2035.
IonQ&#8217;s stock has been on a surge, with the company&#8217;s commitment to building a quantum ecosystem in Texas, following the passage of the Texas Quantum Initiative,&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46175752/ionq-stock-is-surging-monday-whats-driving-the-rally">driving the rally</a>.
Additionally, the company&#8217;s recent scientific achievements—such as advancements in protein folding and particle physics in partnership with the U.S. Department of Defense—highlight the company&#8217;s growing potential in the quantum computing space.
Benzinga Edge Stock Rankings show that IonQ stock had a strong price trend over the short, medium and long term. Its momentum ranking was strong at 9the 9th percentile, whereas its value ranking was poor at the 3rd percentile; the details of other metrics are available <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a>.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46232263/d-wave-surges-1326-whats-driving-quantum-computings-newest-star">D-Wave Surges 1,326%: What&#8217;s Driving Quantum Computing&#8217;s Newest Star? </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

IONQ

This Quantum Computing Stock Just Raised $1 Billion — And Analyst Says It's Only Getting Started

MBAV

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

RLYB

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

<ul>
<li>ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease.</li>
<li>Despite being treated with standard-of-care renal drug therapy (ACEi, SGLT2, statin, and ezetimibe), the patient authorized by FDA to receive VAR 200 is showing continued kidney disease progression. Because her kidney biopsy demonstrated lipid deposition, the treating physician, Dr. Alessia Fornoni, hypothesized that VAR 200 has potential to alleviate lipid accumulation, proteinuria, and disease progression. This is based on VAR 200's consistent results across preclinical studies in three different models of kidney disease, and supporting HPβCD clinical data in patients with lysosomal storage and protein deposition disorders, such as Niemann-Pick disease type C.</li>
<li>VAR 200, currently in a phase 2a clinical trial for diabetic kidney disease (DKD), was designed to passively and actively reduce renal lipid accumulation to protect against renal injury and fibrosis and improve kidney function.</li>
</ul>
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, is pleased to provide regulatory and product support for FDA-authorized Emergency Compassionate Use of Cholesterol Efflux Mediator&#x2122;&nbsp;VAR 200 in a patient with ApoCII amyloidosis. Emergency Compassionate Use, also called Emergency Expanded Access, is a pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational drug for treatment outside of clinical trials when enrollment criteria are not met or there are no comparable or satisfactory alternative therapy options.
The patient with ApoCII amyloidosis will receive treatment at the University of Miami Peggy and Harold Katz Family Drug Discovery Center under the care of the Center Director, Dr. Alessia Fornoni, Professor of Medicine, University of Miami Miller School of Medicine, and VAR 200 inventor. VAR 200 treatment and monitoring will follow the protocol of the ongoing DKD clinical trial, VAR200-0301

ZVSA

ZyVersa Therapeutics Provides Regulatory And Product Support For FDA-Authorized Emergency Compassionate Use Of Cholesterol Efflux Mediator VAR 200 In ApoCII Amyloidosis Patient

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Sophie Karp upgraded the rating for Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Underweight to Sector Weight. Sunrun shares closed at $11.11 on Monday. <a href="https://www.benzinga.com/quote/run/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith upgraded Southwest Gas Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) from Hold to Buy and raised the price target from $74 to $82. Southwest Gas shares closed at $72.88 on Monday. <a href="https://www.benzinga.com/quote/swx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Sophie Karp upgraded SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Underweight to Sector Weight. SolarEdge shares closed at $26.43 on Monday. <a href="https://www.benzinga.com/quote/sedg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert upgraded Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ"> ARTL</a>) from Hold to Buy and announced a $20 price target. Artelo Biosciences shares closed at $14.32 on Monday. <a href="https://www.benzinga.com/quote/artl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SWX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SWX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-1024x583.png" alt="" class="wp-image-976369" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08074652/image-77.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46289573/trump-tariffs-sink-dow-over-400-points-investor-sentiment-declines-but-fear-greed-index-remains-in-extreme-greed-zone">Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear &amp; Greed Index Remains In &#8216;Extreme Greed&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

OSCR

SEDG

VOYG

This Southwest Gas Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Barclays analyst Terry Ma downgrades BrightSpire Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSP#NYSE">BRSP</a>) from Equal-Weight to Underweight and lowers the price target from $7 to $5.

Downgrades

Price Target

BRSP

Barclays Downgrades BrightSpire Capital to Underweight, Lowers Price Target to $5

SAFX

XCF Global Produces Over 2.5M Gallons of SAF, Renewable Diesel, and Naphtha at New Rise Reno Facility During Ramp-Up Phase

Market-Moving Exclusives

Exclusives

CYRX

EXCLUSIVE: Cryoport Tells Benzinga 'New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology'

EXCLUSIVE: Cryoport Tells Benzinga  Co's MVE Biological Solutions Introduces Next Generation Shippers

Cryoport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) on Tuesday announced the launch of MVE Biological Solutions&#8217; new vapor shippers, the SC 4/2V and SC 4/3V.
The company said these shippers offer medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures.
Built on MVE&#8217;s legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and 4/3V models have been redesigned utilizing innovative technologies to offer customers added protection during extended or challenging shipments.
Also Read: <a target="_blank" href="https://www.benzinga.com/node/45722755" rel="noreferrer noopener">Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date</a>
These four-liter vapor shippers are engineered to safely transport critical biological materials such as cells and tissue for cell therapies, biopharma, reproductive health materials, and animal health materials, including vaccines while maintaining the materials&#8217; integrity throughout the journey.
According to the company, the new SC 4/2V and SC 4/3V vapor shipper models include several key advancements designed to enhance performance and reliability.
Hold times for both next-generation models have been significantly extended to 19 days for the SC 4/2V (previously 13 days) and 26 days for the SC 4/3V (up from 21 days), providing greater flexibility and security during transit delays, the company claims.
MVE&#8217;s patented &#8220;BEND DON&#8217;T BREAK&#8221; technology features a specially designed top that flexes under stress, absorbing impact to reduce the risk of damage during rough handling that sometimes happens during shipping.
Other upgraded features of the new vapor shippers include a newly integrated lid-locking tab that helps prevent breakage and MVE&#8217;s patent-pending &#8220;Vapor Shield Technology,&#8221; which minimizes the risk of vacuum loss caused by liquid nitrogen overfilling.
In May, CryoPort reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45265771/cryoport-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">first-quarter revenue</a> growth of 10.1% to $41.04 million, missing the analyst consensus estimate of $44.69 million. The company reduced its quarterly net loss to $14.0 million, or&nbsp;28&nbsp;cents per share, down from &nbsp;$20.9 million, or 43 cents per share, a year ago.
The company lowered its fiscal 2025 sales&nbsp;outlook&nbsp;from&nbsp;$240.00 million to $250.00 million&nbsp;to $165.00 million to $172.00 million, compared to the $186.04 million&nbsp;estimate.
CryoPort stock lost close to 9% in value year-to-date.
Price Action: CYRX stock closed lower by 4.83% at $7.290 on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46283392/what-fueled-robloxs-85-surge-in-2025" target="_blank" rel="noreferrer noopener">What Fueled Roblox&#8217;s 85% Surge In 2025?</a></li>
</ul>
Photo by MacroEcon via Shutterstock

EXCLUSIVE: Cryoport Boosts Cold Chain Tech With New Shippers Designed For Delays And Rough Handling

Jefferies analyst Julien Dumoulin-Smith upgrades Southwest Gas Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) from Hold to Buy and raises the price target from $74 to $82.

Jefferies Upgrades Southwest Gas Hldgs to Buy, Raises Price Target to $82

Jefferies analyst James Wheatcroft reinstates Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy and announces $380 price target.

Initiation

FLUT

Jefferies Reinstates Buy on Flutter Entertainment, Announces $380 Price Target

Looking ahead to 2026, Soligenix is positioning itself for a pivotal year marked by key clinical milestones and potential catalysts across its rare disease pipeline. Most notably, the company anticipates releasing top-line results from its confirmatory Phase 3 FLASH2 trial of HyBryte&#x2122; for early-stage cutaneous T-cell lymphoma in the second half of the year. With enrollment on track and prior data showing promising efficacy and safety, the outcome of FLASH2 could be transformational for HyBryte's regulatory and commercial trajectory. Soligenix is also actively exploring strategic partnerships and M&amp;A opportunities to maximize value creation, while targeting global marketing authorizations. Backed by a diversified pipeline, solid early clinical data, and an expanding manufacturing footprint, the company sees 2026 as a potential inflection point in its mission to deliver impactful therapies for underserved patient populations.
&nbsp;
&nbsp;

SNGX

Soligenix Issues Corporate Update Highlighting FLASH2 Phase 3 Progress, Psoriasis and Behçet's Trial Milestones, and Strategic Outlook Through 2026

ARWR

Arrowhead Pharmaceuticals Doses First Patient In Pivotal YOSEMITE Phase 3 Trial Of RNAi-Based Zodasiran For Homozygous Familial Hypercholesterolemia

WIIM

BCTX

BriaCell shares are trading higher after the company reported a 52% one-year survival rate in its Phase 2 metastatic breast cancer trial.

Jefferies analyst Surinder Thind downgrades WNS (Holdings) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) from Buy to Hold and lowers the price target from $80 to $76.5.

Jefferies Downgrades WNS (Holdings) to Hold, Lowers Price Target to $76.5

LakeShore Biopharma shares are trading higher after the company announced a $15 million private placement financing.

BriaCell Reports 52% One-Year Survival in Phase 2 Metastatic Breast Cancer Trial, Surpassing Standard of Care in Heavily Pre-Treated Patients

Financing

LakeShore Biopharma Enters $15M Share And Warrant Purchase Agreement With Institutional Investor

Martin Marietta  Appoints Michael J. Petro as Chief Financial Officer, Succeeding Interim CFO Robert J. Cardin Effective Immediately

CK HUTCH HLD LTD ORD by CK Hutchison Holdings LTD

CK Hutchison Holdings

Comments

CK Hutchison Holdings

Noticias

Últimas noticias sobre CK Hutchison Holdings (OTC:CKHUF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL